These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12234264)

  • 21. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
    Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
    Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
    Anderson LD; Cook DR; Yamamoto TN; Berger C; Maloney DG; Riddell SR
    Cancer Immunol Immunother; 2011 Jul; 60(7):985-97. PubMed ID: 21461886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
    Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
    Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
    Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
    Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
    Wu L; Zhang H; Jiang Y; Gallo RC; Cheng H
    Proc Natl Acad Sci U S A; 2018 May; 115(19):E4453-E4462. PubMed ID: 29674449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
    Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer.
    Amir AL; van der Steen DM; van Loenen MM; Hagedoorn RS; de Boer R; Kester MD; de Ru AH; Lugthart GJ; van Kooten C; Hiemstra PS; Jedema I; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
    Clin Cancer Res; 2011 Sep; 17(17):5615-25. PubMed ID: 21771875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
    Kwak LW; Neelapu SS; Bishop MR
    Semin Oncol; 2004 Feb; 31(1):37-46. PubMed ID: 14970936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
    Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
    Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
    Dörrschuck A; Schmidt A; Schnürer E; Glückmann M; Albrecht C; Wölfel C; Lennerz V; Lifke A; Di Natale C; Ranieri E; Gesualdo L; Huber C; Karas M; Wölfel T; Herr W
    Blood; 2004 Oct; 104(8):2591-9. PubMed ID: 15231579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
    Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
    Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
    Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.
    Leaf RK; Stroopinsky D; Pyzer AR; Kruisbeek AM; van Wetering S; Washington A; Ephraim A; Cole L; Morin A; Jain S; Nahas MR; Apel A; Arnason J; Hamdan A; Rosenblatt J; Avigan D
    J Immunother; 2017; 40(9):315-322. PubMed ID: 28961609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.
    van Bergen CA; Kester MG; Jedema I; Heemskerk MH; van Luxemburg-Heijs SA; Kloosterboer FM; Marijt WA; de Ru AH; Schaafsma MR; Willemze R; van Veelen PA; Falkenburg JH
    Blood; 2007 May; 109(9):4089-96. PubMed ID: 17234742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect.
    Circosta P; Vitaggio K; Elia AR; Todorovic M; Sangiolo D; Carnevale-Schianca F; Vallario A; Geuna M; Aglietta M; Cignetti A
    Immunotherapy; 2018 Jul; 10(9):753-767. PubMed ID: 30008257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.